Compass Therapeutics Inc (NASDAQ:CMPX) shares, rose in value on Thursday, March 27, with the stock price up by 2.94% to the previous day’s close as strong demand from buyers drove the stock to $2.10.
Actively observing the price movement in the last trading, the stock closed the session at $2.04, falling within a range of $2.0 and $2.15. The value of beta (5-year monthly) was 0.999. Referring to stock’s 52-week performance, its high was $4.08, and the low was $0.76. On the whole, CMPX has fluctuated by -29.29% over the past month.
With the market capitalization of Compass Therapeutics Inc currently standing at about $290.39 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CMPX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of CMPX currently trading nearly -14.24% and -26.11% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.00, while the 7-day volatility ratio is showing 7.55% which for the 30-day chart, stands at 8.01%. Furthermore, Compass Therapeutics Inc (CMPX)’s beta value is 1.13, and its average true range (ATR) is 0.21.
A comparison of Compass Therapeutics Inc (CMPX) with its peers suggests the former has fared considerably weaker in the market. CMPX showed an intraday change of 2.94% in last session, and over the past year, it grew by 2.44%%.
Data on historical trading for Compass Therapeutics Inc (NASDAQ:CMPX) indicates that the trading volumes over the past 10 days have averaged 0.96 and over the past 3 months, they’ve averaged 1.53 million. According to company’s latest data on outstanding shares, there are 137.82 million shares outstanding.
Nearly 41.64% of Compass Therapeutics Inc’s shares belong to company insiders and institutional investors own 38.87% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.61 million shares as on 2025-03-14, resulting in a short ratio of 5.43. According to the data, the short interest in Compass Therapeutics Inc (CMPX) stood at 470.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 3.53 million. The stock has risen by 44.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CMPX stock heading into the next quarter.
